clinical trial · NCT06742138
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 284
Multiple MyelomaQL2109PomalidomideDexamethasoneDARZALEX FASPRO®
brief summary
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.
started
Jan 1, 2025
primary completion
Dec 1, 2027
completion
Dec 1, 2028
last updated
Dec 19, 2024
official title
A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL2109/ DARZALEX FASPRO® in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol